Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | DAO | P14920 | 3/20 | 0.56 |
| ▸ | ELANE | P08246 | 3/20 | 0.56 |
| ▸ | TYR | P14679 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7558334 | 0.97 | POLB (0.63) | POLBGAADAOELANETYR | |
| SCHEMBL3220810 | 0.90 | DAO (0.63) | POLBGAADAOELANETYR | |
| SCHEMBL361231 | 0.89 | POLB (0.61) | POLBGAADAOELANETYR | |
| SCHEMBL28313263 | 0.88 | POLB (0.64) | POLBGAADAOELANETYR | |
| SCHEMBL7550581 | 0.87 | POLB (0.60) | POLBGAADAOELANETYR | |
| SCHEMBL360885 | 0.85 | POLB (0.57) | POLBGAADAOELANETYR | |
| SCHEMBL7551138 | 0.83 | POLB (0.53) | POLBGAADAOELANETYR | |
| SCHEMBL7554264 | 0.83 | DAO (0.54) | POLBGAADAOELANETYR | |
| SCHEMBL9085769 | 0.83 | SERPINE1 (0.56) | DAOELANETYR | |
| SCHEMBL361245 | 0.80 | DAO (0.58) | DAOELANETYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7188206-A | — | — | None | — | — | JP | disclosed |
| US-20120014894-A1 | Compositions and Methods for Treating Hyperpigmentation | REVANCE THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| EP-2379177-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION | Revance Therapeutics, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010078244-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION | REVANCE THERAPEUTICS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100166689-A1 | Compositions and Methods for Treating Hyperpigmentation | REVANCE THERAPEUTICS, INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-5523421-A | TYROSINASE INHIBITORS; SKIN WHITENERS | PACIFIC CORPORATION (KR) | 1996-06-04 | — | — | US | disclosed |
| JP-H07188206-A | KOJIC ACID DERIVATIVE | PACIFIC CORP | 1995-07-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014894-A1 | Compositions and Methods for Treating Hyperpigmentation | TYR, CUTA, SLC25A21 | POLB 1386/4885GAA 677/4885DAO 794/4885 |
| US-20100166689-A1 | Compositions and Methods for Treating Hyperpigmentation | TYR, CUTA, SLC25A21 | POLB 1386/4885GAA 677/4885DAO 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.